Life or Profit? How Global Companies Exploit India’s Medical Device Gaps

The Hidden Crisis: How Global Giants Exploit India's Medical Device Regulatory Gaps - And Why Lives Are at Stake

By Ankur K. Khare – Biomedical Engineer | AI Ethics & Medical Innovation

The shocking truth behind India's medical device regulation failures that's putting millions of patients at risk

The Johnson & Johnson Scandal That Exposed Everything

When Jennifer Bharucha finally won her decade-long legal battle against Johnson & Johnson in September 2024, receiving ₹35 lakh in compensation for her mother's suffering from a faulty hip implant, it marked more than just a personal victory. It exposed the terrifying reality of India's medical device regulatory system - one where 4,700 Indian patients received defective implants that continued to be sold for three years after a global recall.

But this isn't just about one company or one device. It's about a systemic failure that's being exploited by global manufacturers while Indian patients pay the ultimate price.

The Three-Year Delay That Cost Lives

The numbers are staggering and shameful:

·         August 2010: Johnson & Johnson recalls ASR hip implants globally due to alarming failure rates

·         2013: India finally revokes the import license - three years later

·         4,700 Indian patients: Received these defective implants during this delay period

·         76% of affected patients: Still remain untraceable today

·         ₹25 lakh vs ₹1.2 crore: The compensation disparity between what J&J offered versus what the government demanded

This delay wasn't just bureaucratic inefficiency - it was a catastrophic regulatory failure that highlighted how global manufacturers can exploit India's weak oversight mechanisms.

The Regulatory Swiss Cheese: Gaps That Kill

1. The Free Sale Certificate Loophole

Here's the shocking reality: Under India's Medical Device Rules 2017, foreign companies can skip clinical trials in India if they have approval from the US, EU, Australia, Japan, or Canada. While this sounds efficient, it creates a dangerous dependency on foreign regulatory decisions.

The J&J case proves this system is fatally flawed. Despite having approvals from these "trusted" countries, the device was still defective. Yet India blindly accepted these approvals without additional scrutiny.

2. No Centralized Patient Registry

Unlike countries such as the UK, Australia, and Sweden that maintain robust patient registries, India has no centralized system to track who receives which medical devices. When the J&J recall happened:

·         Authorities had to rely on newspaper advertisements to inform patients

·         76% of affected patients could not be traced

·         Many patients discovered their implants were defective only after experiencing severe complications

3. Voluntary Reporting System

The Materiovigilance Programme of India (MvPI) makes adverse event reporting optional, not mandatory. This means:

·         Device failures often go unreported

·         Patterns of defects are missed

·         Dangerous devices remain in circulation longer

·         Regulatory action is delayed by years

4. Toothless Enforcement

Even when violations are discovered, penalties are often inadequate. The Medical Device Rules 2017 lack enforceable penalties for manufacturers who fail to meet post-market surveillance obligations.

The Chinese Device Security Threat: A New Dimension of Risk

While India struggles with basic regulatory oversight, a new threat has emerged that shows how these gaps can be weaponized for national security risks.

China is now India's second-largest medical device supplier with ₹11,506 crore worth of imports in 2023-24. Government investigations reveal alarming possibilities:

·         IoT-enabled medical devices that could leak sensitive health data

·         Malware and surveillance capabilities embedded in devices

·         Defense installation vulnerabilities where Chinese devices are used

·         Remote activation of malicious code whenever desired

The fact that these concerns are only being investigated now, after years of unchecked imports, shows how reactive rather than proactive India's regulatory approach has been.

The Drugs, Medical Devices and Cosmetics Bill 2022: Too Little, Too Late?

The proposed new bill attempts to address some of these issues, but critical gaps remain:

What It Gets Right:

·         Establishes dedicated medical device technical advisory boards

·         Creates separate testing facilities for medical devices

·         Introduces uniform regulations for all device classes

·         Includes telemedicine and digital health provisions

What It Still Misses:

·         No mandatory clinical trials for devices with foreign approvals

·         Weak patient registry provisions compared to international standards

·         Insufficient penalties for non-compliance

·         No dedicated medical device authority (still clubbed with drugs and cosmetics)

The Price Control Controversy: Safety vs Affordability

Adding another layer of complexity, India's price control mechanisms have created unintended consequences:

·         Coronary stents prices capped since 2017, but hospitals now charge more for procedures

·         Knee implant prices reduced by 50-70%, but quality concerns emerge

·         US trade complaints about India not considering innovation costs in pricing

·         Limited annual price increases (only 1.74% for stents in 2025) discourage innovation investment

This creates a dangerous equation: while making devices affordable, are we inadvertently encouraging the import of lower-quality devices to meet price points?

Real Stories, Real Consequences

Beyond statistics lie human stories:

·         Jennifer Bharucha's mother underwent multiple revision surgeries due to the faulty J&J implant

·         Thousands of patients living with metal poisoning from defective hip implants

·         Rural hospitals unknowingly using Chinese devices that could compromise patient data

·         Untraceable patients who may never receive the compensation or medical care they deserve

The Global Exploitation Model

Here's how global manufacturers exploit India's regulatory weaknesses:

1.       Regulatory Arbitrage: Use India as a "softer" market for devices that face scrutiny elsewhere

2.      Delayed Compliance: Continue selling products even after global recalls, knowing enforcement is weak

3.      Data Harvesting: Especially with IoT devices, collect patient data with minimal oversight

4.      Price Dumping: Flood the market with low-cost devices that may compromise on quality

5.       Legal Forum Shopping: Challenge Indian regulations in international forums while exploiting local gaps

The CDSCO Approval Backlog Crisis

Current data shows alarming delays in regulatory approvals:

·         Thousands of applications pending across multiple CDSCO divisions

·         6-12 month approval timelines that often stretch longer

·         Documentation requirements that vary by region

·         No standardized digital processing despite digitization promises

This creates a perfect storm: legitimate manufacturers face delays while exploitative actors find workarounds.

Five Critical Reforms India Needs NOW

1. Mandatory Domestic Clinical Trials

All medical devices, regardless of foreign approvals, should undergo mandatory clinical investigation tailored to Indian population genetics and healthcare conditions.

2. Centralized Patient Registry

Establish a comprehensive, digitized registry tracking every medical device implanted in India, similar to Sweden's model.

3. Independent Medical Device Authority

Create a separate regulatory body for medical devices, independent from drug regulation, with specialized expertise and adequate funding.

4. Mandatory Adverse Event Reporting

Make device failure reporting mandatory with significant penalties for non-compliance, supported by automated digital reporting systems.

5. Real-Time Global Surveillance

Establish mechanisms to instantly implement recalls and safety actions when devices are flagged globally, without the 3-year delays seen in the J&J case.

The Economic Argument: Why Better Regulation Helps Everyone

Contrary to industry fears, stronger regulation actually benefits the medical device ecosystem:

·         Increased investor confidence in Indian manufacturers

·         Higher export potential with global-standard compliance

·         Reduced litigation costs from device failures

·         Enhanced medical tourism reputation

·         Innovation incentives for genuine manufacturers

The National Security Imperative

With medical devices increasingly connected to networks and storing sensitive data, regulatory gaps become national security vulnerabilities. The current investigation into Chinese devices should have happened years ago, not after extensive market penetration.

What Patients Can Do Right Now

While waiting for regulatory reform:

1.       Demand device traceability - ask for complete documentation of any implanted device

2.      Research manufacturers - check for any global recalls or safety issues

3.      Seek second opinions for major device implantations

4.      Document everything - maintain detailed records of all medical devices received

5.       Report adverse events - use available channels to report device-related problems

The Path Forward: A Regulatory Renaissance

India stands at a critical juncture. The medical device industry is projected to reach $50 billion by 2030, making it crucial that regulatory frameworks match this growth. The choice is clear:

Continue with the current patchwork system that allows exploitation and puts patients at risk, or implement comprehensive reforms that protect patients while fostering innovation.

The J&J scandal was a wake-up call. The Chinese device security concerns are the alarm bell.

How many more patients must suffer before India acts decisively?

The Bottom Line

India's medical device regulatory gaps aren't just bureaucratic inefficiencies - they're life-and-death vulnerabilities being actively exploited by global manufacturers. From three-year recall delays to security-compromised devices, the current system fails patients while enabling corporate exploitation.

The Drugs, Medical Devices and Cosmetics Bill 2022 offers hope, but only if it addresses these fundamental gaps with enforceable mechanisms, dedicated expertise, and patient-first priorities.

The question isn't whether India can afford comprehensive medical device regulation. The question is whether India can afford not to have it.

The lives of millions of patients depend on getting this right. The time for half-measures and delayed responses is over.

This investigation reveals the systematic weaknesses in India's medical device regulatory framework that have already cost lives and continue to put patients at risk. Share this article to demand better protection for Indian patients and accountability from global manufacturers.